Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer

Background/Aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week cycl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:In Vivo
Main Authors: KOKKALI, STEFANIA, TRIPODAKI, ELLI-SOPHIA, DRIZOU, MARIA, STEFANOU, DIMITRA, MAGOU, ELPIDA, ZYLIS, DIMOSTHENIS, KAPIRIS, MATTHAIOS, NASI, DESPOINA, GEORGANTA, CHARA, ARDAVANIS, ALEXANDROS
Formato: Artigo
Idioma:Inglês
Publicado em: International Institute of Anticancer Research 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000799/
https://ncbi.nlm.nih.gov/pubmed/29695574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.112289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados